The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
Open accessAbstract
BACKGROUND: A limited or absent bronchodilator response is used to classify chronic obstructive pulmonary disease (COPD) and can determine the treatment offered. The reliability of the recommended response criteria and their relationship to disease progression has not been established. METHODS: 660 patients meeting European Respiratory Society (ERS) diagnostic criteria for irreversible COPD were studied. Spirometric parameters were measured on three occasions before and after salbutamol and ipratropium bromide sequentially or in combination over 2 months. Responses were classified using the American Thoracic Society/GOLD (ATS) and ERS criteria. Patients were followed for 3 years with post-bronchodilator FEV(1) and exacerbation history recorded 3 monthly and health status 6 monthly. RESULTS: FEV(1) increased significantly with each bronchodilator, a response that was normally distributed. Mean post-bronchodilator FEV(1) was reproducible between visits (intraclass correlation 0.93). The absolute change in FEV(1) was independent of the pre-bronchodilator value but the percentage change correlated with pre-bronchodilator FEV(1) (r=-0.44; p<0.0001). Using ATS criteria, 52.1% of patients changed responder status between visits compared with 38.2% using ERS criteria. Smoking status, atopy, and withdrawing inhaled corticosteroids were unrelated to bronchodilator response, as was the rate of decline in FEV(1), decline in health status, and exacerbation rate. CONCLUSION: In moderate to severe COPD bronchodilator responsiveness is a continuous variable. Classifying patients as "responders" and "non-responders" can be misleading and does not predict disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Self-citationLung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
(1993) · PubMed · Cited by 3,827
Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease
Celli, B. R., Snider, G. L., Heffner, J. E., Tiep, B. L., Ziment, I., Make, B. J., Braman, S. S., Olsen, G. N., & D, Y. Y. P. M. (1995) · Cited by 3,506
An Introduction to Medical Statistics.
(1931) · Journal of the American Medical Association · doi:10.1001/jama.1931.02730150055037 · Cited by 2,084
Siafakas, N., Vermeire, P., Pride, N., Paoletti, P., Gibson, J., Howard, P., Yernault, J., Decramer, M., Higenbottam, T., Postma, D., et al. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081398 · Cited by 1,592
Pauwels, R. A., Löfdahl, C.-G., Laitinen, L. A., Schouten, J. P., Postma, D. S., Pride, N. B., & Ohlsson, S. V. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402503 · Cited by 1,074
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
“Despite earlier hopes, neither bronchodilator nor oral glucocorticosteroid reversibility testing predicts disease progression, whether judged by decline in FEV1, deterioration of health status, or frequency of exacerbations (67, 68) in patients with a clinical diagnosis of COPD and abnormal spirometry (68).”
BackgroundSelf-citationChanges in Forced Expiratory Volume in 1 Second over Time in COPD
Vestbo, J., Edwards, L. D., Scanlon, P. D., Yates, J. C., Agusti, A., Bakke, P., Calverley, P. M. A., Celli, B., Coxson, H. O., Crim, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105482 · Cited by 963
Self-citationOutcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
Self-citationManagement of Chronic Obstructive Pulmonary Disease
Sutherland, E. R., & Cherniack, R. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030415 · Cited by 563
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Yang, I. A., Clarke, M. S., Sim, E. H., & Fong, K. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002991.pub3 · Cited by 523
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Kew, K. M., & Seniukovich, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010115.pub2 · Cited by 398
What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion
Sin, D. D., Miravitlles, M., Mannino, D. M., Soriano, J. B., Price, D., Celli, B. R., Leung, J. M., Nakano, Y., Park, H. Y., Wark, P. A., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00436-2016 · Cited by 367
Jenkins, C. R., Jones, P. W., Calverley, P. M., Celli, B., Anderson, J. A., Ferguson, G. T., Yates, J. C., Willits, L. R., & Vestbo, J. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-59 · Cited by 345
Self-citationShahab, L., Jarvis, M. J., Britton, J., & West, R. (2006) · Thorax · doi:10.1136/thx.2006.064410 · Cited by 324
Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study
Terzikhan, N., Verhamme, K. M. C., Hofman, A., Stricker, B. H., Brusselle, G. G., & Lahousse, L. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0132-z · Cited by 306
García-Río, F., Calle, M., Burgos, F., Casan, P., del Campo, F., Galdiz, J. B., Giner, J., González-Mangado, N., Ortega, F., & Puente Maestu, L. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.04.001 · Cited by 283
Nannini, L. J., Poole, P., Milan, S. J., Holmes, R., & Normansell, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub4 · Cited by 274
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Leigh, R., Pizzichini, M. M. M., Morris, M. M., Maltais, F., Hargreave, F. E., & Pizzichini, E. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00072105 · Cited by 272
Nannini, L. J., Lasserson, T. J., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006829.pub2 · Cited by 264
Monitoring mast cell activation by prostaglandin D2 in vivo
Dahlen, S.-E. (2004) · Thorax · doi:10.1136/thx.2004.026641 · Cited by 77
Effects of formoterol on exercise tolerance in severely disabled patients with COPD
Neder, J. A., Fuld, J. P., Overend, T., Thirlwell, J., Carter, R., Stevenson, R., & Ward, S. A. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.06.006 · Cited by 47
“0 [25–170]W.”
Metadata
- Authors
- Calverley, P. M. A.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2003-08-01
- Volume
- 58
- Issue
- 8
- Pages
- 659-664
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2143454168
- Cited by
- 512
- References
- 29
- FWCI
- 33.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.